Literature DB >> 410823

Compensatory increase in TSH secretion without effect on prolactin secretion in patients treated with aminoglutethimide.

R J Santen, S A Wells, N Cohn, L M Demers, R I Misbin, E L Foltz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 410823     DOI： 10.1210/jcem-45-4-739

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  9 in total

Review 1.  Could aminoglutethimide replace adrenalectomy?

Authors:  A L Harris
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

2.  Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma.

Authors:  S A Wells; R J Santen; A Lipton; D E Haagensen; E J Ruby; H Harvey; W G Dilley
Journal:  Ann Surg       Date:  1978-05       Impact factor: 12.969

Review 3.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 4.  Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review.

Authors:  R J Santen
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

Review 5.  Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.

Authors:  E Samojlik; J D Veldhuis; S A Wells; R J Santen
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

Review 6.  First generation aromatase inhibitors--aminoglutethimide and testololactone.

Authors:  G Cocconi
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

7.  Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.

Authors:  P E Lønning; S Kvinnsland; T Thorsen; P M Ueland
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

8.  Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.

Authors:  M Dowsett; F MacNeill; A Mehta; C Newton; B Haynes; A Jones; M Jarman; P Lonning; T J Powles; R C Coombes
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

9.  Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.

Authors:  A L Harris; M Dowsett; I E Smith; S Jeffcoate
Journal:  Br J Cancer       Date:  1983-10       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.